Salim Abed Hussein, Oghenemaro Enwa Felix, Kubaev Aziz, Jeddoa Zuhair Mohammed Ali, S RenukaJyothi, Sharma Shilpa, Vashishth Raghav, Jabir Majid S, Jawad Sabrean Farhan, Zwamel Ahmed Hussein
Department of Medical Laboratory Techniques, Al-Maarif University College, Al-Anbar, Ramadi, Iraq.
Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Delta State University, Abraka, Delta State, Nigeria.
Cell Biochem Biophys. 2025 Jun;83(2):1359-1374. doi: 10.1007/s12013-024-01585-2. Epub 2024 Oct 19.
Inflammatory bowel disease (IBD) is an idiopathic disease caused by a dysregulated immune response to host intestinal microflora. A hyperactive inflammatory and immunological response in the gut has been shown to be one of the disease's long-term causes despite the complexity of the clinical pathology of IBD. The innate immune system activator known as human gut inflammasome is thought to be a significant underlying cause of pathology and is closely linked to the development of IBD. It is essential to comprehend the function of inflammasome activation in IBD to treat it effectively. Systemic inflammasome regulation may be a proper therapeutic and clinical strategy to manage IBD symptoms since inflammasomes may have a significant function in IBD. Non-coding RNAs (ncRNAs) are a type of RNA transcript that is incapable of encoding proteins or peptides. In IBD, inflammation develops and worsens as a result of its imbalance. Culminating evidence has been shown that ncRNAs, and particularly long non-coding RNAs (lncRNAs), may play a role in the regulation of NLR family pyrin domain containing 3 (NLRP3) inflammasome activation in IBD. The relationship between IBD and the gut inflammasome, as well as current developments in IBD research and treatment approaches, have been the main topics of this review. We have covered inflammasomes and their constituents, results from in vivo research, inflammasome inhibitors, and advancements in inflammasome-targeted therapeutics for IBD.
炎症性肠病（IBD）是一种由对宿主肠道微生物群的免疫反应失调引起的特发性疾病。尽管IBD临床病理学复杂，但肠道中过度活跃的炎症和免疫反应已被证明是该疾病的长期病因之一。被称为人类肠道炎性小体的先天免疫系统激活剂被认为是病理的一个重要潜在原因，并且与IBD的发展密切相关。有效治疗IBD必须了解炎性小体激活在其中的作用。由于炎性小体可能在IBD中起重要作用，全身炎性小体调节可能是管理IBD症状的一种合适的治疗和临床策略。非编码RNA（ncRNA）是一种无法编码蛋白质或肽的RNA转录本。在IBD中，炎症因其失衡而发展和恶化。越来越多的证据表明，ncRNA，尤其是长链非编码RNA（lncRNA），可能在IBD中调节含NLR家族pyrin结构域3（NLRP3）炎性小体的激活中发挥作用。IBD与肠道炎性小体之间的关系，以及IBD研究和治疗方法的当前进展，一直是本综述的主要主题。我们涵盖了炎性小体及其成分、体内研究结果、炎性小体抑制剂以及针对IBD的炎性小体靶向治疗的进展。
